Document is current
Any future updates will be listed below
-
Authors
Freedman, Joshua D
Hagel, Joachim
Scott, Eleanor M
Psallidas, Ioannis
Gupta, Avinash
Spiers, Laura
Miller, Paul
Kanellakis, Nikolaos https://orcid.org/0000-0002-0065-2282
Ashfield, Rebecca
Fisher, Kerry D
Duffy, Margaret R
Seymour, Leonard W https://orcid.org/0000-0003-3825-0841
-
Funding
Funding for this research was provided by:
Cancer Research UK (C552/A17720)
RCUK|Medical Research Council
Kay Kendall Leukaemia Fund (KKL1050)
- License Information
-
More Information
Article History
Received: 11 January 2017
Revised: 15 May 2017
Accepted: 18 May 2017
First Online: 20 June 2017
Conflict of interest
: K.D.F. and L.W.S. own equity or share options in PsiOxus Therapeutics, which is leading clinical development of EnAd and its derivatives.
